Advertisement
Singapore markets close in 4 hours 29 minutes

  • Straits Times Index

    3,168.93
    -18.73 (-0.59%)
     

  • Nikkei

    37,097.37
    -982.33 (-2.58%)
     

  • Hang Seng

    16,184.02
    -201.85 (-1.23%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Bitcoin USD

    62,189.37
    +175.99 (+0.28%)
     

  • CMC Crypto 200

    1,287.00
    +401.47 (+44.12%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,403.30
    +5.30 (+0.22%)
     

  • Crude Oil

    84.66
    +1.93 (+2.33%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • FTSE Bursa Malaysia

    1,550.13
    +5.37 (+0.35%)
     

  • Jakarta Composite Index

    7,060.55
    -106.27 (-1.48%)
     

  • PSE Index

    6,411.73
    -111.46 (-1.71%)
     

Will Bio-Rad (BIO) Gain on Rising Earnings Estimates?

Zacks Equity Research
·2-min read

Bio-Rad Laboratories (BIO) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.

The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this maker of instruments used in biomedical research, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. This insight is at the core of our stock rating tool -- the Zacks Rank.

The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.

For Bio-Rad, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.

ADVERTISEMENT

The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:

12 Month EPS

Current-Quarter Estimate Revisions

The earnings estimate of $1.85 per share for the current quarter represents a change of +14.91% from the number reported a year ago.

Over the last 30 days, one estimate has moved higher for Bio-Rad compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 10.12%.

Current-Year Estimate Revisions

For the full year, the earnings estimate of $7.90 per share represents a change of +11.9% from the year-ago number.

In terms of estimate revisions, the trend for the current year also appears quite encouraging for Bio-Rad. Over the past month, one estimate has moved higher compared to no negative revisions, helping the consensus estimate increase 9.72%.

Favorable Zacks Rank

Thanks to promising estimate revisions, Bio-Rad currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.

Bottom Line

Bio-Rad shares have added 9.9% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BioRad Laboratories, Inc. (BIO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.